Payment overview · 2025
General Payments
$359.30
11 reported records · 10 companies
Healthcare provider profile · identity verified
Robert C Schreiman, MD
Allopathic & Osteopathic Physicians|Family Medicine · TUSTIN, CA · NPI 1871605196
Verified facts
What the public records show
CMS Open Payments records show Robert C Schreiman, MD received $359.30 in general payments during 2025 across 11 reported records.
ACADIA Pharmaceuticals Inc accounted for 40.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lumigan by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trulicity by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $144.81 | 40.3% | 2 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$44.29 | 12.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.97 | 8.6% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $25.52 | 7.1% | 1 | 2025 |
| Alvogen Inc | Unresolved — no canonical attribution shown | $24.22 | 6.7% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $20.38 | 5.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.06 | 5.6% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $17.38 | 4.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.86 | 4.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.81 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $359.30 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $144.81 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.97 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $25.52 | 1 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Alvogen Inc | $24.22 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20.38 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.06 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $15.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
135 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 838 | 155 |
| Levothyroxine Sodium | Levothyroxine Sodium | 496 | 83 |
| Amlodipine Besylate | Amlodipine Besylate | 494 | 90 |
| Pantoprazole Sodium | Pantoprazole Sodium | 441 | 78 |
| Eliquis | Apixaban | 401 | 57 |
| Metformin Hcl | Metformin Hcl | 353 | 63 |
| Gabapentin | Gabapentin | 343 | 57 |
| Donepezil Hcl | Donepezil Hcl | 339 | 45 |
| Losartan Potassium | Losartan Potassium | 315 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 281 | 53 |
| Memantine Hcl | Memantine Hcl | 269 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 266 | 49 |
| Famotidine | Famotidine | 265 | 40 |
| Lisinopril | Lisinopril | 252 | 46 |
| Furosemide | Furosemide | 236 | 51 |
| Escitalopram Oxalate | Escitalopram Oxalate | 225 | 34 |
| Mirtazapine | Mirtazapine | 211 | 35 |
| Quetiapine Fumarate | Quetiapine Fumarate | 211 | 33 |
| Divalproex Sodium | Divalproex Sodium | 209 | 28 |
| Omeprazole | Omeprazole | 208 | 37 |
| Levetiracetam | Levetiracetam | 194 | 24 |
| Potassium Chloride | Potassium Chloride | 191 | 39 |
| Trazodone Hcl | Trazodone Hcl | 190 | 41 |
| Xarelto | Rivaroxaban | 174 | 15 |
| Risperidone | Risperidone | 168 | 25 |
| Sertraline Hcl | Sertraline Hcl | 152 | 27 |
| Jardiance | Empagliflozin | 135 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 129 | 23 |
| Olanzapine | Olanzapine | 128 | 14 |
| Memantine Hcl Er | Memantine Hcl | 116 | 12 |
| Carvedilol | Carvedilol | 113 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 111 | 17 |
| Finasteride | Finasteride | 106 | 19 |
| Simvastatin | Simvastatin | 106 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 103 | 22 |
| Baclofen | Baclofen | 100 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 91 | 17 |
| Midodrine Hcl | Midodrine Hcl | 85 | 17 |
| Lorazepam | Lorazepam | 81 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 78 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 77 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 71 | 23 |
| Farxiga | Dapagliflozin Propanediol | 71 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 69 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 67 | suppressed |
| Januvia | Sitagliptin Phosphate | 63 | suppressed |
| Lactulose | Lactulose | 63 | 14 |
| Montelukast Sodium | Montelukast Sodium | 63 | 13 |
| Atenolol | Atenolol | 62 | 15 |
| Allopurinol | Allopurinol | 61 | 11 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 60 | 21 |
| Tramadol Hcl | Tramadol Hcl | 60 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 59 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 58 | 16 |
| Latanoprost | Latanoprost | 57 | 13 |
| Buspirone Hcl | Buspirone Hcl | 56 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 56 | 31 |
| Benazepril Hcl | Benazepril Hcl | 53 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 31 |
| Amiodarone Hcl | Amiodarone Hcl | 47 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 47 | suppressed |
| Alprazolam | Alprazolam | 45 | 11 |
| Aripiprazole | Aripiprazole | 43 | suppressed |
| Humulin R | Insulin Regular, Human | 43 | suppressed |
| Novolin R | Insulin Regular, Human | 43 | suppressed |
| Rivastigmine | Rivastigmine | 43 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 43 | 12 |
| Glipizide | Glipizide | 42 | suppressed |
| Valsartan | Valsartan | 42 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 41 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 40 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 39 | suppressed |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Ibuprofen | Ibuprofen | 38 | 19 |
| Methocarbamol | Methocarbamol | 38 | 13 |
| Celecoxib | Celecoxib | 37 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | 14 |
| Rexulti | Brexpiprazole | 37 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 36 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 17 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 33 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 33 | 13 |
| Levofloxacin | Levofloxacin | 33 | 26 |
| Enoxaparin Sodium | Enoxaparin Sodium | 32 | suppressed |
| Lovastatin | Lovastatin | 32 | suppressed |
| Nystatin | Nystatin | 32 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 31 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Naproxen | Naproxen | 30 | suppressed |
| Digoxin | Digoxin | 29 | suppressed |
| Estradiol | Estradiol | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Azithromycin | Azithromycin | 28 | 21 |
| Daptomycin | Daptomycin | 28 | suppressed |
| Meloxicam | Meloxicam | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 26 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 25 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 25 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 23 | suppressed |
| Vascepa | Icosapent Ethyl | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 12 |
| Gentamicin Sulfate | Gentamicin Sulfate | 21 | 17 |
| Carbamazepine Er | Carbamazepine | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 15 |
| Timolol Maleate | Timolol Maleate | 20 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 18 | suppressed |
| Ursodiol | Ursodiol | 18 | suppressed |
| Valproic Acid | Valproic Acid | 18 | suppressed |
| Amantadine | Amantadine Hcl | 17 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Prednisone | Prednisone | 17 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Anastrozole | Anastrozole | 15 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 15 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Budesonide | Budesonide | 14 | suppressed |
| Entacapone | Entacapone | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Mesalamine | Mesalamine | 13 | suppressed |
| Phenytoin | Phenytoin | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Lumigan | Bimatoprost | 12 | suppressed |
| Mesalamine Dr | Mesalamine | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Asa-Butalb-Caffeine-Codeine | Codeine/Butalbital/Asa/Caffein | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Enulose | Lactulose | 11 | suppressed |
| Ertapenem | Ertapenem Sodium | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Multaq | Dronedarone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $359.30 · 11 records | ACADIA Pharmaceuticals Inc | CAPLYTA, INGREZZA, MAVYRET, NUPLAZID, REPATHA, REXULTI, TERIPARATIDE, UZEDY, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error